SEARCH

SEARCH BY CITATION

References

  • 1
    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 2
    Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 68493.
  • 3
    Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 8835.
  • 4
    Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 21930.
  • 5
    Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Exp Opin Biol Ther 2001; 1: 497510.
  • 6
    Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999; 163: 292836.
  • 7
    Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60: 62725.
  • 8
    Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 707.
  • 9
    Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, et al. Immunological analysis of a phase I/II study of vaccination with a MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3 positive tumors. J Immunother 2004; 27: 12435.
  • 10
    FlemingID, CooperJS, HensonDE, HutterRVP, KennedyBJ, MurphyGP, O'SullivanB, SobinLH, YabroJW, eds. American Joint Committee on Cancer: cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
  • 11
    Weynants P, Lethé B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int J Cancer 1994; 56: 8269.
  • 12
    National Cancer Institute of Canada Clinical Trial Group. Recommendations for grading of acute and subacute toxicity. Toronto: National Cancer Institute of Canada Clinical Trial Group, 1994.
  • 13
    World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 14
    Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 20714.
  • 15
    Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wolfel T, et al. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J Immunol 2005; 174: 240411.
  • 16
    Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 134954.
  • 17
    Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22: 43140.
  • 18
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 19
    Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 166978.
  • 20
    Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Röder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000; 165: 34926.
  • 21
    Toungouz M, Libin M, Bulté F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with Mage-A1/A3-positive tumors. J Leukoc Biol 2001; 69: 93743.
  • 22
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton AJr, Kirkwood JM, McMasters KM, Mihm MF, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 363548.
  • 23
    Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004; 172: 328996.
  • 24
    Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000; 68: 45563.